On Wednesday, ACADIA Pharmaceuticals (ACAD) delivered Q2’s financials. Lower-than-expected expenses resulted in a beat to the bottom-line, with EPS of -$0.27 coming in ahead of the estimates by $0.03. However, the company missed on the top-line by $9.72 million, as revenue increased by 4.7% year-over-year to reach $115.22 million. While normally the results would be investors’ primary focus, in ACADIA’s case, as J.P. Morgan’s Cory Kasimov notes, the “story clearly comes down to the regulatory path for Nuplazid in DRP.
https://www.tipranks.com/news/article/acadia-drp-treatments-path-ahead-unclear-yet-current-risk-reward-appears-favorable?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Acadia Pharmaceuticals Charts.